GIP and obesity due to melanocortin 4 receptor deficiency: Meanwhile, tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is an emerging therapeutic option for type 2 diabetes and obesity (3).